An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics

Trial Profile

An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Cancer pain; Pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 13 Apr 2016 The trial is prematurely ended in Greece, Sweden, Bulgaria and is Ongoing in UK and Germany.
    • 27 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top